Given the overwhelming evidence of serotonergic influence in cognitive function, there has been interest in various 5-HT receptor (5-HTR) agonists and antagonists for the treatment of AD, including 5-HT2A [35,79] and 5-HT6 [37,69]. Here, HTR2A is linked to Alzheimer disease.